Induction therapy with Erlotinib (E) and Gemcitabine/Platinum (GP) in stage III NSCLC
Crossref DOI link: https://doi.org/10.29328/journal.jprr.1001018
Published Online: 2021-01-28
Update policy: https://doi.org/10.29328/journal/jprr
Overbeck, Tobias R
Wenleder, Stefan HP
Danner, Bernhard C
Körber, Wolfgang
Toepelt, Karin
Hemmerlein, Bernhard
Perske, Christina
Falk, Markus
Tiemann, Markus
Tomala, Claudia
Stitz, Elke
Griesinger, Frank
License valid from 2021-01-28
Version of Record valid from 2013-11-25
Accepted Manuscript valid from 2016-04-18
